Subsequent Event (Details Narrative) - Subsequent Event [Member] |
Mar. 25, 2020
USD ($)
|
Mar. 24, 2020
$ / shares
|
Mar. 23, 2020
USD ($)
|
|---|---|---|---|
| COVID-19 Vaccine [Member] | |||
| Royalty payments, description | We shall also make quarterly royalty payments to Sellers equal to 5% of the net sales of a COVID-19 vaccine or combination product by the Company (the "COVID-19 Vaccine") for a period of five (5) years following the first commercial sale of the COVID-19 Vaccine; provided, that such payment shall be reduced to 3% for any net sales of the COVID-19 Vaccine above $500 million. | ||
| Cystron Biotech, LLC [Member] | |||
| Ownership pecentage | 100.00% | ||
| Membership Interest Purchase Agreement [Member] | |||
| Payment to sellers | $ 1,000,000 | ||
| Proceeds from initial equity offering | $ 8,000,000 | ||
| Percenatge of payement to sellers on equity offering | 10.00% | ||
| Additonal cash consideration | $ 10,000,000 | ||
| Acheivment of milestone, description | Upon the achievement of certain milestones, including the completion of a Phase 2 study that meets its primary endpoints, Sellers will be entitled to receive an additional 750,000 shares of our common stock or, in the event we are unable to obtain stockholder approval for the issuance of such shares, 750,000 shares of non-voting preferred stock that are valued following the achievement of such milestones and shall bear a 10% annual dividend (the "Milestone Shares"). Sellers will also be entitled to contingent payments from us of up to $20,750,000 upon the achievement of certain milestones, including the approval of a new drug application by the U.S. Food and Drug Administration ("FDA"). | ||
| Royalty payments to sellers, percentage | 0.125 | ||
| Membership Interest Purchase Agreement [Member] | Cystron Biotech, LLC [Member] | |||
| Ownership pecentage | 100.00% | ||
| Agreement description | As consideration for the Membership Interests, we will deliver to the Sellers: (1) that number of newly issued shares of our common stock equal to 19.9% of the issued and outstanding shares of our common stock and pre-funded warrants as of the date of the MIPA, but, to the extent that the issuance of the our common stock would result in any Seller owning in excess of 4.9% of our outstanding common stock, then, at such Seller's election, such Seller may receive "common stock equivalent" preferred shares with a customary 4.9% blocker (with such common stock and preferred stock collectively referred to as "Common Stock Consideration"), | ||
| Proceeds from collaborators | $ 1,000,000 | ||
| Membership Interest Purchase Agreement [Member] | Cystron Biotech, LLC [Member] | Premas Biotech PVT Ltd [Member] | |||
| Acheivment of milestone, description | Upon the achievement of certain developmental milestones by Cystron, Cystron shall pay to Premas a total of up to $2,000,000. | ||
| Certificate of Designation [Member] | |||
| Preferred stock, stated value | $ / shares | $ 0.01 | ||
| Conversion price, per share | $ / shares | $ .01 |